AIM ImmunoTech (AIM) Cost of Revenue (2010 - 2026)
AIM ImmunoTech's (AIM) quarterly Cost of Revenue came in at $4000.0 in Q1 2026, down 60.0% YoY from $10000.0 in Q1 2025, and down 90.0% on a QoQ basis from $40000.0 in Q4 2025.
AIM ImmunoTech (AIM) Cost of Revenue (2010 - 2026) Analysis & Trends
AIM ImmunoTech (AIM) has 17 years of Cost of Revenue data on file, last reported at $4000.0 in Q1 2026.
- Quarterly Cost of Revenue fell 60.0% year-over-year to $4000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $122000.0 (up 269.7% YoY) and the FY2025 annual result came in at $128000.0, up 312.9% from the prior year.
- Cost of Revenue fell to $4000.0 in Q1 2026, from $40000.0 in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $77000.0 in Q1 2022 to a low of $4000.0 in Q1 2026.
- A 5-year average of $27000.0 and a median of $10000.0 in 2025 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2022 — Cost of Revenue sank 75.27% — and 2025, when it surged 750.0%.
- Tracing AIM's Cost of Revenue over 5 years: stood at $69000.0 in 2022, then tumbled by 82.61% to $12000.0 in 2023, then sank by 41.67% to $7000.0 in 2024, then jumped by 471.43% to $40000.0 in 2025, then sank by 90.0% to $4000.0 in 2026.
- The last three Cost of Revenue figures came in at $4000.0 (Q1 2026), $40000.0 (Q4 2025), and $68000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 145.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 93.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 174.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 298.26 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 387.98 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 67.21 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | AIM ImmunoTech | 4.43 Mn | -5.53 Mn | 21,000.00 | 5,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5,000.00 |
| Jun 30, 2026 | 5,000.00 |
| Mar 31, 2026 | 4,000.00 |
| Mar 31, 2026 | 4,000.00 |
| Dec 31, 2025 | 40,000.00 |
| Dec 31, 2025 | 40,000.00 |
| Sep 30, 2025 | 68,000.00 |
| Sep 30, 2025 | 68,000.00 |
| Jun 30, 2025 | 10,000.00 |
| Jun 30, 2025 | 10,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Mar 31, 2025 | 10,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Dec 31, 2024 | 7,000.00 |
| Sep 30, 2024 | 8,000.00 |
| Sep 30, 2024 | 8,000.00 |
| Jun 30, 2024 | 8,000.00 |
| Jun 30, 2024 | 8,000.00 |
| Mar 31, 2024 | 8,000.00 |
| Mar 31, 2024 | 8,000.00 |